EirGen Pharma Oncology Product Eir-013 submitted in US

EirGen Pharma are pleased to announce that their oncology molecule "Eir-013" was submitted to the Food & Drug Admininstration (FDA) in Dec 2008. This product was successful developed as a treatment for for prostate cancer and passed its fed and fasted clinical trial in the US in Q3 2008.

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.